Christoph H Westphal
CIK 1291961 · President and CEO · last filed 2021-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.20M
Companies
5
Total Filings
106
Lifetime Open-Market Net
$13.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TCRX | 10%+ Owner | 1,036,585 | $0.77 | $796.4K | $2.00M | 1 | 2021-07-22 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | President and CEO | 157,645 | — | — | $3.19M | 65 | 2018-10-18 |
| VSTM | Executive Chairman | 65,911 | $6.08 | $400.7K | $8.08M | 28 | 2015-07-01 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 47,118 | — | — | $1.05M | 3 | 2014-03-11 |
| Sirtris Pharmaceuticals, Inc. (SIRT) Delisted | President and CEO | 744,053 | — | — | -$733.3K | 8 | 2008-05-30 |
Recent Filings · Page 2 of 11
106 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-13 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +6,000 | $71.6K | EDGAR |
| 2016-06-09 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +5,900 | $72.3K | EDGAR |
| 2016-06-07 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +6,000 | $75.4K | EDGAR |
| 2016-06-02 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +10,000 | $129.9K | EDGAR |
| 2016-06-01 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +22,300 | $282.7K | EDGAR |
| 2016-05-27 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +28,600 | $367.2K | EDGAR |
| 2016-05-24 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +30,334 | $376.6K | EDGAR |
| 2016-05-23 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +7,914 | $87.5K | EDGAR |
| 2016-05-19 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +33,400 | $370.7K | EDGAR |
| 2016-05-17 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Buy (P) | +15,469 | $158.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.